Login to Your Account

Other News To Note

Thursday, October 3, 2013

An in vivo study by Biothera Inc., of Eagan, Minn., showed that Imprime PGG enhances the antitumor function of immune cells and directs a percentage of them to the tumor microenvironment. Imprime PGG is designed as an immunomodulator and is being developed for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription